These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29501959)

  • 1. Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations.
    González-Casacuberta I; Morén C; Juárez-Flores DL; Esteve-Codina A; Sierra C; Catalán-García M; Guitart-Mampel M; Tobías E; Milisenda JC; Pont-Sunyer C; Martí MJ; Cardellach F; Tolosa E; Artuch R; Ezquerra M; Fernández-Santiago R; Garrabou G
    Neurobiol Aging; 2018 May; 65():206-216. PubMed ID: 29501959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations.
    González-Casacuberta I; Juárez-Flores DL; Ezquerra M; Fucho R; Catalán-García M; Guitart-Mampel M; Tobías E; García-Ruiz C; Fernández-Checa JC; Tolosa E; Martí MJ; Grau JM; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    Aging (Albany NY); 2019 Jun; 11(11):3750-3767. PubMed ID: 31180333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygous PRKN mutations are common but do not increase the risk of Parkinson's disease.
    Zhu W; Huang X; Yoon E; Bandres-Ciga S; Blauwendraat C; Billingsley KJ; Cade JH; Wu BP; Williams VH; Schindler AB; Brooks J; Gibbs JR; Hernandez DG; Ehrlich D; Singleton AB; Narendra DP
    Brain; 2022 Jun; 145(6):2077-2091. PubMed ID: 35640906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons.
    Schwartzentruber A; Boschian C; Lopes FM; Myszczynska MA; New EJ; Beyrath J; Smeitink J; Ferraiuolo L; Mortiboys H
    Sci Rep; 2020 Sep; 10(1):15485. PubMed ID: 32968089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRKN, DJ-1, and PINK1 screening identifies novel splice site mutation in PRKN and two novel DJ-1 mutations.
    Ghazavi F; Fazlali Z; Banihosseini SS; Hosseini SR; Kazemi MH; Shojaee S; Parsa K; Sadeghi H; Sina F; Rohani M; Shahidi GA; Ghaemi N; Ronaghi M; Elahi E
    Mov Disord; 2011 Jan; 26(1):80-9. PubMed ID: 21322020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkin mutation decreases neurite complexity and maturation in neurons derived from human fibroblasts.
    Pu J; Gao T; Zheng R; Fang Y; Ruan Y; Jin C; Shen T; Tian J; Zhang B
    Brain Res Bull; 2020 Jun; 159():9-15. PubMed ID: 32156628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson's Disease Arising from Parkin Mutations.
    Li D; Aung-Htut MT; Ham KA; Fletcher S; Wilton SD
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease.
    Ross OA; Haugarvoll K; Stone JT; Heckman MG; White LR; Aasly JO; Mark Gibson J; Lynch T; Wszolek ZK; Uitti RJ; Farrer MJ
    Parkinsonism Relat Disord; 2007 Oct; 13(7):386-8. PubMed ID: 17400506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Daida K; Funayama M; Billingsley KJ; Malik L; Miano-Burkhardt A; Leonard HL; Makarious MB; Iwaki H; Ding J; Gibbs JR; Ishiguro M; Yoshino H; Ogaki K; Oyama G; Nishioka K; Nonaka R; Akamatsu W; Blauwendraat C; Hattori N
    Mov Disord; 2023 Dec; 38(12):2249-2257. PubMed ID: 37926948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.
    Lubbe SJ; Bustos BI; Hu J; Krainc D; Joseph T; Hehir J; Tan M; Zhang W; Escott-Price V; Williams NM; Blauwendraat C; Singleton AB; Morris HR;
    Hum Mol Genet; 2021 Mar; 30(1):78-86. PubMed ID: 33448283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial impairment observed in fibroblasts from South African Parkinson's disease patients with parkin mutations.
    van der Merwe C; Loos B; Swart C; Kinnear C; Henning F; van der Merwe L; Pillay K; Muller N; Zaharie D; Engelbrecht L; Carr J; Bardien S
    Biochem Biophys Res Commun; 2014 May; 447(2):334-40. PubMed ID: 24721425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism.
    Borsche M; König IR; Delcambre S; Petrucci S; Balck A; Brüggemann N; Zimprich A; Wasner K; Pereira SL; Avenali M; Deuschle C; Badanjak K; Ghelfi J; Gasser T; Kasten M; Rosenstiel P; Lohmann K; Brockmann K; Valente EM; Youle RJ; Grünewald A; Klein C
    Brain; 2020 Oct; 143(10):3041-3051. PubMed ID: 33029617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation analysis of the PARKIN, PINK1, DJ1, and SNCA genes in Turkish early-onset Parkinson's patients and genotype-phenotype correlations.
    Erer S; Egeli U; Zarifoglu M; Tezcan G; Cecener G; Tunca B; Ak S; Demirdogen E; Kenangil G; Kaleagası H; Dogu O; Saka E; Elibol B
    Clin Neurol Neurosurg; 2016 Sep; 148():147-53. PubMed ID: 27455133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRKN-linked familial Parkinson's disease: cellular and molecular mechanisms of disease-linked variants.
    Clausen L; Okarmus J; Voutsinos V; Meyer M; Lindorff-Larsen K; Hartmann-Petersen R
    Cell Mol Life Sci; 2024 May; 81(1):223. PubMed ID: 38767677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Papagiannakis N; Liu H; Koros C; Simitsi AM; Stamelou M; Maniati M; Buena-Atienza E; Kartanou C; Karadima G; Makrythanasis P; Vatsellas G; Valente EM; Gasser T; Stefanis L
    Mov Disord; 2024 Apr; 39(4):715-722. PubMed ID: 38357851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene.
    Pavan C; Jin J; Jong S; Strbenac D; Davis RL; Sue CM; Johnston J; Lynch T; Halliday G; Kirik D; Parish CL; Thompson LH; Ovchinnikov DA
    Stem Cell Res; 2023 Dec; 73():103211. PubMed ID: 37890334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
    Halder T; Verma SP; Raj J; Pandey S; Singh RK; Sharma V; Joshi D; Das P
    Indian J Med Res; 2020 Nov; 152(5):498-507. PubMed ID: 33707392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations.
    Deng H; Le WD; Hunter CB; Ondo WG; Guo Y; Xie WJ; Jankovic J
    Arch Neurol; 2006 Feb; 63(2):273-7. PubMed ID: 16476817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profiling of parkin-mutant human skin fibroblasts.
    Lobasso S; Tanzarella P; Vergara D; Maffia M; Cocco T; Corcelli A
    J Cell Physiol; 2017 Dec; 232(12):3540-3551. PubMed ID: 28109117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.